Noticias Financieras

ndtvhace 8d

¿Por qué OpenAI está pausando los planes de Chat GPT erótico? Todo lo que necesitas saber

OpenAI ha archivado sus planes de introducir el modo erótico en ChatGPT.

#TECH

e27hace 8d

Cómo las startups de SEA convirtieron lo remoto en una cultura escalable

La era pospandémica no acabó con la cultura de oficina. De hecho, reescribió lo que alguna vez se conoció como la “cultura de trabajo estándar”. Ahora el mundo conoce una cultura de oficina que prioriza el control remoto. Especialmente en el Sudeste Asiático (SEA), donde convergen las presiones de costos y crecimiento, una cultura de prioridad remota es una estrategia de crecimiento deliberada. Pero, ¿qué significa realmente ahora "primero lo remoto" y qué [...] La publicación Cómo las nuevas empresas de SEA convirtieron lo remoto primero en una cultura escalable apareció por primera vez en e27.

#TECH

bitcoinworldhace 8d

La impresionante pérdida neta de 14,8 millones de dólares de BitGo en 2025 revela la vulnerabilidad de valoración de Bitcoin de la criptoinfraestructura

La impresionante pérdida neta de $14,8 millones de BitcoinWorld BitGo en 2025 revela la vulnerabilidad de valoración de Bitcoin de Crypto Infrastructure PALO ALTO, California, 15 de marzo de 2025 – El líder en infraestructura de criptomonedas BitGo ha informado una importante pérdida neta de $14,8 millones para el año fiscal 2025, un resultado financiero que contrasta marcadamente con su explosivo crecimiento de ingresos del 424% a $16,15 mil millones. Este resultado paradójico, confirmado por datos financieros informados por BeInCrypto, se deriva directamente de una sustancial suma de $50 [...] Esta publicación La impresionante pérdida neta de $14,8 millones de BitGo en 2025 revela la vulnerabilidad de valoración de Bitcoin de Crypto Infrastructure apareció por primera vez en BitcoinWorld.

#ECONOMY

scmphace 8d

La economía de China es lo suficientemente grande como para absorber los impactos de la guerra de Irán, dice Justin Lin

China tiene suficiente capacidad para absorber los shocks externos de la guerra de Irán y cumplir su objetivo de crecimiento económico anual, dijo un destacado economista, añadiendo que también se estaba preparando para la posibilidad de que Washington pudiera incumplir sus acuerdos comerciales. Justin Lin Yifu, decano del Instituto de Nueva Economía Estructural de la Universidad de Pekín y ex economista jefe del Banco Mundial, dijo el jueves que ningún país podría librarse de los impactos económicos del conflicto en Oriente Medio, que...

#ECONOMY

seekingalphahace 8d

Carta de Harry Qelm Baabsman para el año fiscal 2025 a los inversores

La rentabilidad del +31,71% de Steppe Eagle OEIC en 2025 superó al MSCI World en un 12,22%.

#ECONOMY

fxstreethace 8d

Tasa de desempleo en México aumenta a 2,7% en febrero desde 2,6% anterior

Tasa de desempleo en México aumenta a 2,7% en febrero desde 2,6% anterior

#COMMODITIES#ECONOMY

theguardianhace 8d

La nueva moneda Trump tendrá un águila en el reverso. Aquí hay algunas opciones mejores | David Schilling

La verdadera imagen definitoria de esta presidencia debería ser el extracto bancario del ciudadano estadounidense promedio. Sorprendentemente, inexplicablemente, Donald Trump sigue encontrando nuevos lugares donde poner su rostro. Además, su nombre. O iniciales. O uno de esos dibujos de pavo que hace un niño trazando el contorno de su mano. Tiene su salón de baile, el Kennedy Center, y un arco de 250 pies propuesto que se convertiría en uno de los edificios más altos de todo Washington DC, una ciudad con restricciones de altura para el desarrollo desde hace mucho tiempo. Su firma será en dólares estadounidenses a finales de este año, por primera vez para un presidente en ejercicio. Le preguntaría si se estaba cansando de toda la atención, pero creo que sabemos la respuesta. Lo siguiente es una moneda de oro conmemorativa, con un valor exacto de 1 dólar, que muestra el rostro ceñudo de Trump que se cierne amenazadoramente sobre el escritorio Resolute en la Oficina Oval. Es una pose bastante clásica de Trump, diseñada para hacer que un hombre de casi 80 años con una variedad de moretones misteriosos que come McDonald's con regularidad parezca físicamente intimidante. Más allá del presidente que luce un puchero clásico de la generación Z, la Comisión de Bellas Artes (un panel designado por Ya sabes quién) recomendó que esta moneda sea "lo más grande posible", lo que inmediatamente me hace pensar en el centavo gigante que Bruce Wayne guarda en la Baticueva. Buena suerte intentando alimentar un parquímetro con eso. Dave Schilling es un escritor y humorista radicado en Los Ángeles. Continuar leyendo...

#COMMODITIES#ECONOMY

euronexthace 8d

Comunicado de prensa: La formulación subcutánea Sarclisa de Sanofi administrada mediante un inyector corporal recomendada para la aprobación de la UE por parte del CHMP para tratar el mieloma múltiple

Press Release: Sanofi’s Sarclisa subcutaneous formulation administered via on-body injector recommended for EU approval by the CHMP to treat multiple myeloma Stocks master_of_puppets Fri 27/03/2026 - 13:00 FR0000120578 FR0000120578 FR0000120578 27/03/2026 - 13:00 Paris Press Release: Sanofi’s Sarclisa subcutaneous formulation administered via on-body injector recommended for EU approval by the CHMP to treat multiple myeloma Other subject 1001172659-en GlobeNewswire Sanofi Winthrop Industrie Euronext Published 20103015 Pharmaceuticals XPAR BGEM ETLX Language English <p align="justify"><i>Sanofi’s Sarclisa subcutaneous formulation administered via on-body injector recommended for EU approval by the CHMP to treat multiple myeloma</i></p> <ul type="disc"><li style="text-align:left;">Recommendation based on positive results demonstrating comparable efficacy, pharmacokinetics, and safety of Sarclisa regimens administered subcutaneously compared to intravenous infusion</li><li style="text-align:left;">If approved, Sarclisa subcutaneous (SC) would be the first available anticancer treatment to be administered through an on-body injector (OBI), and the first multiple myeloma medicine available by both SC OBI and manual injection in the EU</li></ul> <p align="justify"><b>Paris, March 27, 2026.</b> The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the approval of Sarclisa (isatuximab) subcutaneous (SC) in combination with approved standard-of-care regimens for the treatment of patients with multiple myeloma (MM) across all currently approved indications for Sarclisa intravenous (IV) formulation in the EU. If approved, Sarclisa would be the first available anticancer treatment to be administered through both an on-body injector (OBI) and manual injection, and the only anti-CD38 monoclonal antibody available in MM to offer the flexibility of both an OBI and manual injection. A final decision is expected in the coming months.</p> <p align="justify"><i>“This positive CHMP opinion is a pivotal milestone in our mission to improve the treatment experience for multiple myeloma patients and providers,” </i>says <b>Olivier Nataf,</b> Global Head of Oncology at Sanofi.<i> “Our aim is to evolve the treatment experience by combining the clinically proven efficacy of Sarclisa with innovative subcutaneous delivery via an on-body injector. This advancement reflects our unwavering commitment to patients and dedication to transforming care in ways that truly matter to people living with cancer.”</i></p> <p align="justify">The positive CHMP opinion is based on the <a href=" https://www.sanofi.com/assets/dotcom/pressreleases/2025/2025-06-03-12-2... ; rel="nofollow" target="_blank">results</a> from the IRAKLIA phase 3 study in relapsed and/or refractory (R/R) MM (clinical study identifier: <a href=" https://www.clinicaltrials.gov/ct2/show/NCT05405166" ; rel="nofollow" target="_blank">NCT05405166</a>), which demonstrated non‐inferiority of the SC formulation compared to the IV formulation. Four additional studies supported the decision and include the GMMG-HD8 phase 3 study in transplant-eligible newly diagnosed MM (NDMM, TE) (clinical study identifier: <a href=" https://clinicaltrials.gov/study/NCT05804032" ; rel="nofollow" target="_blank">NCT05804032</a>), the IZALCO phase 2 study in R/R MM (clinical study identifier: <a href=" https://www.clinicaltrials.gov/study/NCT05704049" ; rel="nofollow" target="_blank">NCT05704049</a>), and the ISASOCUT phase 2 study in transplant-ineligible NDMM (NDMM, TI) (clinical study identifier: <a href=" https://www.clinicaltrials.gov/study/NCT05889221" ; rel="nofollow" target="_blank">NCT05889221</a>) and one phase 1b study in R/R MM patients who received at least two prior lines of therapy (clinical study identifier: <a href=" https://clinicaltrials.gov/study/NCT04045795" ; rel="nofollow" target="_blank">NCT04045795</a>).</p> <p align="justify">Of the multiple SC studies two studies showed the use of Sarclisa SC + OBI was associated with greater patient satisfaction compared to IV administration, and patient and healthcare provider preference compared to Sarclisa manual injection, based on patient experience and satisfaction questionnaires fielded in the studies.</p> <p align="justify">These collective results provide comprehensive evidence supporting the potential use of Sarclisa SC + OBI to advance patient care in NDMM and R/R MM, while maintaining Sarclisa’s strong efficacy and safety profile.</p> <p align="justify">The studies were conducted using Enable Injections’ enFuse^® hands-free OBI, an automated injector designed to deliver subcutaneously high-volume medicines beginning with the push of a button, to administer Sarclisa SC formulation. The enFuse device uses a thinner and retractable needle that is smaller compared to the needles commonly used for large-volume injections, which may help support patient comfort.</p> <p align="justify">Sarclisa IV is currently approved in four indications in the EU for both NDMM, TI and NDMM, TE, and as early as first relapse in R/R MM. In addition to the EU, a regulatory submission is also under review with the US Food and Drug Administration (FDA).</p> <p align="justify">Sarclisa SC + OBI or manual injection is currently under clinical investigation, and its safety and efficacy have not been evaluated by any regulatory authority.<br /> <br /><b>About the IRAKLIA study<br /></b>IRAKLIA (clinical study identifier: <a href=" https://www.clinicaltrials.gov/ct2/show/NCT05405166" ; rel="nofollow" target="_blank">NCT05405166</a>) was a randomized, open-label, pivotal phase 3 study evaluating the non-inferiority of Sarclisa SC formulation administered at a fixed dose SC via an OBI versus weight-based dosed Sarclisa IV in combination with pomalidomide and dexamethasone (Pd) in adult patients with R/R MM who have received at least one prior line of therapy. The co-primary outcomes assessed were objective response rate (ORR), according to the 2016 International Myeloma Working Group (IMWG) criteria assessed by Independent Review Committee (IRC) and observed Sarclisa concentrations before dosing (C trough) at steady state (pre-dose at cycle 6, day 1 [C6D1]).<br /><b><br />About the IZALCO study<br /></b>IZALCO (clinical study identifier: <a href=" https://www.clinicaltrials.gov/study/NCT05704049" ; rel="nofollow" target="_blank">NCT05704049</a>) was a two-part, randomized, open-label phase 2 study evaluating the efficacy and safety of Sarclisa SC administered via the OBI or by manual injection, in combination with carfilzomib and Kd, for the treatment of adult patients with R/R MM who have received one to three prior lines of therapy. The primary objective is ORR, as assessed by IRC. The key secondary endpoint is patient preference for the Sarclisa SC administered via an OBI versus manual administration of Sarclisa SC. Healthcare provider preference of delivery method is also assessed as exploratory endpoint.<br /><b><br />About the ISASOCUT study<br /></b>ISASOCOUT (clinical study identifier: <a href=" https://www.clinicaltrials.gov/study/NCT05889221" ; rel="nofollow" target="_blank">NCT05889221</a>) is an open-label phase 2 study assessing Sarclisa SC administered via the OBI in combination with bortezomib, lenalidomide and dexamethasone (VRd) in NDMM patients ineligible for autologous stem-cell transplant (ASCT). The primary objective is rate of very good partial response (VGPR) or better, according to the 2016 IMWG criteria assessed by IRC. The study is ongoing.<b><br /><br />About the GMMG-HD8 study<br /></b>GMMG-HD8 (clinical study identifier: <a href=" https://clinicaltrials.gov/study/NCT05804032" ; rel="nofollow" target="_blank">NCT05804032</a>) was a randomized, open-label, multicenter phase 3 study evaluating the non-inferiority of Sarclisa SC administered via an OBI versus Sarclisa IV, both in combination with VRd at induction, for the treatment of patients with NDMM eligible for ASCT. The primary endpoint of the study is non-inferiority of SC to IV administration as measured by VGPR or better after induction therapy. Results from an interim analysis were submitted to support the conversion of the indication from Sarclisa IV to Sarclisa SC.<b><br /><br />About Enable Injections<br /></b>Cincinnati-based Enable Injections is a global healthcare innovation company committed to improving the patient treatment experience through the development and manufacturing of the enFuse® On-Body Delivery System. An innovative wearable technology, the enFuse system is designed to deliver large volumes of pharmaceutical and biologic therapeutics via subcutaneous administration, with the aim of improving convenience, supporting superior outcomes, and advancing healthcare system economics. <br /><br /><b>About Sarclisa<br /></b>Sarclisa (isatuximab) is approved in more than 50 countries, including in the US, EU, Japan, and China, across multiple treatment lines for MM. Based on the ICARIA-MM phase 3 study, Sarclisa is approved in the US, and Japan in combination with Pd for the treatment of patients with R/R MM who have received ≥two prior therapies, including lenalidomide and a proteasome inhibitor. Additionally, Sarclisa is approved in the EU in combination with Pd for the treatment of patients with R/R MM who have received ≥two prior therapies, including lenalidomide and a proteasome inhibitor and have relapsed on the last therapy, and in China for patients who have received at least one prior line of therapy, including lenalidomide and a proteasome inhibitor. Based on the IKEMA phase 3 study, Sarclisa is also approved in more than 50 countries in combination with Kd, including in the US for the treatment of patients with R/R MM who have received one to three prior lines of therapy and in the EU for patients with MM who have received at least one prior therapy. In the US, EU, and China, Sarclisa is approved in combination with VRd as a front-line treatment option in transplant-ineligible NDMM patients, based on the IMROZ phase 3 study. Sarclisa is also approved in the EU in combination with VRd as an induction treatment for transplant-eligible NDMM patients, based on the GMMG-HD7 phase 3 study. In Japan, Sarclisa is approved in combination with VRd as a front-line treatment option regardless of transplant eligibility.<br /><br />At Sanofi, we are building on a long-standing commitment to oncology as we continue to chase the miracles of science to improve the lives of those living with cancer. We are committed to transforming cancer care by developing innovative, first and best-in-class immunological and targeted therapies for rare and difficult-to-treat cancers with high unmet need.<br /><br />For more information on Sarclisa clinical studies, please visit <a href=" http://www.clinicaltrials.gov" ; rel="nofollow" target="_blank"> www.clinicaltrials.gov</a>.<br /><br /><br /></p> <p align="justify"><i><br /><br />About Sanofi</i> <br />Sanofi is an R&D driven, AI-powered biopharma company committed to improving people’s lives and delivering compelling growth. We apply our deep understanding of the immune system to invent medicines and vaccines that treat and protect millions of people around the world, with an innovative pipeline that could benefit millions more. Our team is guided by one purpose: we chase the miracles of science to improve people’s lives; this inspires us to drive progress and deliver positive impact for our people and the communities we serve, by addressing the most urgent healthcare, environmental, and societal challenges of our time.<br />Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY </p> <p align="justify"><i>Media Relations</i><br /><b>Sandrine Guendoul</b> | +33 6 25 09 14 25 | <a href=" mailto:sandrine.guendoul@sanofi.com" ; rel="nofollow" target="_blank"><u> sandrine.guendoul@sanofi.com </u></a> <br /><b>Evan Berland</b> | +1 215 432 0234 | <a href=" mailto:evan.berland@sanofi.com" ; rel="nofollow" target="_blank"><u> evan.berland@sanofi.com </u></a> <br /><b>Léo Le Bourhis</b> | +33 6 75 06 43 81 | <a href=" mailto:leo.lebourhis@sanofi.com" ; rel="nofollow" target="_blank"><u> leo.lebourhis@sanofi.com </u></a> <br /><b>Victor Rouault</b> | +1 617 356 4751 | <a href=" mailto:victor.rouault@sanofi.com" ; rel="nofollow" target="_blank"><u> victor.rouault@sanofi.com </u></a> <br /><b>Timothy Gilbert</b> | +1 516 521 2929 | <a href=" mailto:timothy.gilbert@sanofi.com" ; rel="nofollow" target="_blank"><u> timothy.gilbert@sanofi.com </u></a> <br /><b>Léa Ubaldi </b>| +33 6 30 19 66 46 | <a href=" mailto:lea.ubaldi@sanofi.com" ; rel="nofollow" target="_blank"><u> lea.ubaldi@sanofi.com </u></a><br /><b>Ekaterina Pesheva</b> | +1 410 926 6780 | <u> ekaterina.pescheva@sanofi.com </u></p> <p align="justify"><i>Investor Relations</i><br /><b>Thomas Kudsk Larsen</b> |+ 44 7545 513 693 | <a href=" mailto:thomas.larsen@sanofi.com" ; rel="nofollow" target="_blank"> thomas.larsen@sanofi.com </a><br /><b>Alizé Kaisserian</b> | + 33 6 47 04 12 11 | <a href=" mailto:alize.kaisserian@sanofi.com" ; rel="nofollow" target="_blank"> alize.kaisserian@sanofi.com </a> <br /><b>Keita Browne</b> | + 1 781 249 1766 | <a href=" mailto:keita.browne@sanofi.com" ; rel="nofollow" target="_blank"> keita.browne@sanofi.com </a> <br /><b>Nathalie Pham</b> | + 33 7 85 93 30 17 | <a href=" mailto:nathalie.pham@sanofi.com" ; rel="nofollow" target="_blank"> nathalie.pham@sanofi.com </a> <br /><b>Nina Goworek</b> | +1 908 569 7086 | <a href=" mailto:nina.goworek@sanofi.com" ; rel="nofollow" target="_blank"> nina.goworek@sanofi.com </a> <br /><b>Thibaud Châtelet</b> | + 33 6 80 80 89 90 | <a href=" mailto:thibaud.chatelet@sanofi.com" ; rel="nofollow" target="_blank"> thibaud.chatelet@sanofi.com </a> <br /><b>Yun Li</b> | +33 6 84 00 90 72 | <a href=" mailto:yun.li3@sanofi.com" ; rel="nofollow" target="_blank"> yun.li3@sanofi.com </a></p> <p align="justify"><b>Sanofi forward-looking statements</b><br />This press release contains forward-looking statements within the meaning of applicable securities laws, including the Private Securities Litigation Reform Act of 1995, as amended. <br />Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions regarding the marketing and other potential of the product; regarding potential future events and revenues from the product. Words such as “expect,” “anticipate,” “believe,” “intend,” “estimate,” “plan,” “can,” “contemplate,” “could,” “is designed to,” “may,” “might,” “potential,” “objective,” "attempt," “target,” “project,” "strategy," "strive," "desire," “predict,” “forecast,” “ambition,” “guideline,” "seek," “should,” “will,” "goal," or the negative of these and similar expressions are intended to identify forward-looking statements. <br />Although Sanofi’s management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks, uncertainties and assumptions include among other things, unexpected regulatory actions or delays, or government regulation generally, that could affect the availability or commercial potential of the product, the fact that product may not be commercially successful; authorities’ decisions regarding whether and when to approve a product candidate; political pressure in the United States to mandate lower drug prices including “most favored nation” pricing for State Medicaid programs; the uncertainties inherent in research and development, including future clinical data and analysis of existing clinical data relating to the product, including post marketing, unexpected safety, quality or manufacturing issues; competition in general; risks associated with intellectual property and any related pending or future litigation and the ultimate outcome of such litigation, and volatile economic and market conditions, and the impact that global crises may have on us, our customers, suppliers, vendors, and other business partners, and the financial condition of any one of them, as well as on our employees and on the global economy as a whole. The risks and uncertainties also include the uncertainties discussed or identified in the public filings with the SEC and the French Markets Authority (AMF) made by Sanofi, including those listed under “Risk Factors” and “Cautionary Statement Regarding Forward-Looking Statements” in Sanofi’s annual report on Form 20-F for the year ended December 31, 2025 or contained in our periodic reports on Form 6-K. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements. In light of these risks, uncertainties and assumptions, you should not place undue reliance on any forward-looking statements contained herein.</p> <p align="justify">All trademarks mentioned in this press release are the property of the Sanofi group with the exception of enFuse.</p> <p><br /> </p> <p id="gnw_attachments_section-header"> <strong>Attachment</strong> </p> <ul id="gnw_attachments_section-items"> <li> <a target="_blank" href=" https://ml-eu.globenewswire.com/Resource/Download/5f68eda4-5929-458a-83... ; </li> </ul> <img alt="" class="__GNW8366DE3E__IMG" src=" https://www.globenewswire.com/newsroom/ti?nf=MTAwMTE3MjY1OSM0MDIzNjU1Nz... ; /> <br/><img alt="" src=" https://ml-eu.globenewswire.com/media/MjM2YTdkOTctYmYyMS00YjhlLTkwNTUtY... ; referrerpolicy="no-referrer-when-downgrade" /> SANOFI SANOFI 078526 FR0000120578-XPAR FR0000120578-BGEM FR0000120578-ETLX SAN 1SAN 4SAN

#ECONOMY

benzingahace 8d

BTCS informa un crecimiento interanual de ingresos del 305% para registrar $ 16,5 millones para todo el año 2025

<link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css" /> <p>WAYNE, Pa., March 27, 2026 (GLOBE NEWSWIRE) -- BTCS Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/BTCS" rel="nofollow">BTCS</a>) ("BTCS" or the "Company"), short for Blockchain Technology Consensus Solutions, a company focused on blockchain infrastructure and decentralized finance operations, today announced its financial results for the year ended December 31, 2025 ("FY 2025"). The Company also released an updated investor presentation available at <a href="https://www.globenewswire.com/Tracker?data=5QqH4MzooAxSTbunJ_npRnAgTQrZq7NdLTBqzy4JFZB_fhuQptHpO30sb_CMLhy-GRWMJnMhydQb_zLEP7W5wtDEVxrnO9mmaW5Fl7lHNYA=" rel="nofollow" target="_blank" rel="nofollow">www.btcs.com/investors/</a>.</p> <p>"<em>2025 was a transformative year for BTCS as we scaled our Ethereum-first operating model and delivered record revenue,"</em> said Charles Allen, Chief Executive Officer of BTCS. "<em>Revenue grew over 300%, driven by the expansion of Builder+, our block-building business, and the successful launch of Imperium, our decentralized finance segment. Rather than relying on staking income alone, we are actively deploying digital assets across infrastructure and DeFi to build durable, recurring revenue streams. Our focus remains on disciplined execution as we scale operations and become profitable</em>."</p> <p><strong>Financial Highlights</strong></p> <p><strong>Full Year 2025 Financial Highlights</strong>^{<strong>1</strong>}</p> <ul type="disc"> <li>Revenue increased <strong>305% </strong>to <strong>$16.5 million</strong>, compared to $4.1 million in 2024. Revenue growth during 2025 was driven primarily by the continued expansion of Builder+ block-building operations and staking activities, along with the Q3'25 launch of Imperium decentralized finance activities.</li> <li>Blockchain infrastructure revenue, comprised of staking (NodeOps) and block-building (Builder+) operations, totaled <strong>$15.2 million</strong>, representing approximately 92% of total revenue, driven primarily by the continued expansion of Builder+ block-building operations as transaction activity and blockspace demand across the Ethereum ecosystem increased.</li> <li>DeFi revenue totaled approximately $1.3 million, representing approximately 8% of total revenue, following the launch of Imperium and its initial scaling during 2025.</li> <li>Gross profit increased to approximately $2.0 million from $0.9 million in 2024; however, gross margin declined to approximately 12% from 23% in the prior year, primarily reflecting higher validator payments and infrastructure costs associated with scaling Builder+ operations.</li> </ul> <p><strong>Balance Sheet Highlights</strong></p> <ul type="disc"> <li>Total assets increased over <strong>460%</strong> to approximately <strong>$214.6 million</strong> at December 31, 2025, reflecting expansion of the Company's digital asset holdings, infrastructure operations, and the use of equity and debt financing during the year.</li> <li>Ethereum (ETH) holdings increased to 70,787 ETH at December 31, 2025, representing a <strong>680%</strong> year-over-year increase.</li> <li>Total liabilities increased to approximately $75.2 million as of December 31, 2025, primarily reflecting ETH-backed borrowings through decentralized finance protocols and convertible notes issued during the year.</li> <li>Common shares outstanding increased to 46.9 million during 2025 as the Company raised capital through its at-the-market program while also repurchasing shares under its previously announced share repurchase program.</li> <li>As of March 22, 2026, the Company's total cash and digital asset balance totaled $126.4 million, inclusive of 57,633 ETH, and total debt obligations amounted to $61.8 million.<br /></li> </ul> <p>Michael Prevoznik, Chief Financial Officer of BTCS, stated, "<em>2025 demonstrated the scalability of our infrastructure-focused business model. Revenue from Builder+ and staking grew significantly, while Imperium added a new, higher-margin revenue stream. Our focus in 2026 remains on expanding these higher-margin opportunities while maintaining disciplined capital management. In response to recent market volatility, we proactively reduced leverage by approximately $18.7 million, bringing our total debt to $61.8 million."</em></p> <p><strong>Operational Highlights </strong></p> <ul type="disc"> <li>In Q3'25, BTCS launched Imperium, a decentralized finance operating segment focused on deploying digital assets into DeFi protocols as a liquidity provider and market participant.</li> <li>Throughout the year, BTCS partnered with several companies including MetaMask, ETHGas, and NuConstruct to further expand order flow for the Company's block building business.</li> <li>BTCS became the first public company to integrate Aave, a leading decentralized lending and borrowing platform into its operations.</li> <li>In Q1'26, BTCS expanded Imperium through integrations with Sorella Labs and Gauntlet to further expand on-chain liquidity provision opportunities and high-margin revenue generation.</li> </ul> <p>Ben Hunter, Chief Technology Officer of BTCS, emphasized, "<em>The blockchain ecosystem has continued to evolve, and we believe that BTCS is well-positioned through our infrastructure capabilities and DeFi initiatives to pursue long-term growth opportunities across the Ethereum economy. In 2025, BTCS partnered with companies across the industry to strengthen and scale our blockchain technology stack, supporting the continued development of our Ethereum-focused strategy."</em></p> <p><strong>Company Commentary and Outlook</strong></p> <p>BTCS entered 2026 focused on scaling Imperium, its higher-margin decentralized finance business line. In support of this objective, the Company realigned its 2026 performance incentive program to place greater emphasis on profitability, including a new gross profit target of $6 million, which represents approximately three times 2025 levels. This focus is intended to better align executives, employees, and shareholders as BTCS continues to build a long-term, sustainable, and profitable business model.</p> <p>Builder+ was the primary driver of revenue growth in 2025, as the Company expanded its participation in Ethereum block-building markets and increased order-flow relationships across the ecosystem. While blockspace markets remained competitive, management believes that continued investment in scale and order-flow relationships will strengthen BTCS's market position and support margin expansion and long-term growth.</p> <p>In 2026, the Company expects Imperium to represent a larger proportion of total revenue, following its launch in the second half of 2025 and as it continues to scale into the new year. As a higher-margin business line, Imperium is expected to play an increasingly important role in the Company's operating model by enabling deployment of digital assets across decentralized finance protocols to generate liquidity provision fees and other protocol-based income.</p> <p>Mr. Allen added, "<em>As the Company's largest shareholder, my goal is to build long-term value through disciplined execution and sustainable growth. We believe this is achieved not simply by accumulating digital assets or relying on asset price appreciation, but by actively generating recurring, high-margin revenue from our infrastructure and DeFi operations.</em> <em>This operating approach differentiates BTCS in the public markets and supports stockholder value creation."</em></p> <p><strong>About BTCS:</strong><br />BTCS Inc. ("BTCS" or the "Company"), short for Blockchain Technology Consensus Solutions, is a U.S.-based Ethereum-first blockchain technology company committed to driving scalable revenue and asset accumulation through its hallmark strategy, the DeFi/TradFi Accretion Flywheel, an integrated approach to capital formation and blockchain infrastructure. By combining decentralized finance ("DeFi") and traditional finance ("TradFi") mechanisms with its blockchain infrastructure operations, comprising NodeOps (staking), Builder+ (block building), and Imperium (DeFi deployments), BTCS offers a unique opportunity for blockchain exposure, driven by recurring on-chain revenue generation and an Ethereum-focused strategy. Discover how BTCS offers exposure to Ethereum and its on-chain economy through the public markets at <a href="https://www.globenewswire.com/Tracker?data=5QqH4MzooAxSTbunJ_npRjHUZ70scqGB9YJp1_STng2pL6AWGQHtPiQKsLzZnh5yqMWZ0g7g4opBFi0Q9SG6Iw==" rel="nofollow" target="_blank" rel="nofollow">www.btcs.com</a>.</p> <p><strong>Forward-Looking Statements:</strong><br />Certain statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws, including statements regarding providing value to shareholders, growth (including revenue growth), long-term value creation, expected results from Imperium, improving margins, the Company's 2026 gross profit target, becoming profitable, expectations regarding Imperium representing a larger proportion of total revenue in 2026, beliefs regarding the Company's market position, expectations for margin expansion, the scalability of the Company's business model, the Company's ability to generate recurring revenue streams, and management's beliefs regarding the benefits of continued investment in scale and order-flow partnerships. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend," "positioned," "focus," "target" or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward-looking statements are based upon assumptions and are subject to various risks and uncertainties, including without limitation: regulatory issues affecting digital assets and blockchain technology; volatility in the market price for ETH and other digital assets; competition in block-building and DeFi markets; unexpected issues with Builder+ or Imperium operations; technological implementation challenges; cybersecurity risks; smart contract vulnerabilities; counterparty risks in DeFi protocols; potential loss of digital assets; liquidity risks associated with DeFi lending and borrowing activities; risks related to the Company's use of leverage; fluctuations in transaction volumes and blockspace demand on the Ethereum network; risks related to changes in Ethereum network protocols or consensus mechanisms; and other risks set forth in the Company's filings with the Securities and Exchange Commission, including its Form 10-K for the year ended December 31, 2025, which was filed on March 26, 2026. Thus, actual results could be materially different. The Company expressly disclaims any obligation to update or alter statements, whether as a result of new information, future events, or otherwise, except as required by law.</p> <p><strong>For more information, follow us on:</strong><br />X: <a href="https://www.globenewswire.com/Tracker?data=4v6FPDJwnVe4nuSh5gdPAZqa-zuHF3iSqIZw-irxrOeYOMnEK9c6iM7ihmDTCXj6OacyYkJDC_Q8iHaEgI9rYGCIV5Xg2LtpS24WQ62IqQE=" rel="nofollow" target="_blank" rel="nofollow">https://x.com/NasdaqBTCS</a><br />LinkedIn: <a href="https://www.globenewswire.com/Tracker?data=4v6FPDJwnVe4nuSh5gdPATgF__g8blSTqJ2iGdp5hfKWqPp1TcBpW284QBg5nZNMscNPq4toxJLI7hUsEivGMHSXgIsqQagFYnjAzhnlxNyTOEsFFDmE2h-Z1UNMRER28umKGb-qqG6nXAOSgK7dtiJMdcCVx_n_eJ4ZzpFmUpQ=" rel="nofollow" target="_blank" rel="nofollow">https://www.linkedin.com/company/nasdaq-btcs</a><br />Facebook: <a href="https://www.globenewswire.com/Tracker?data=4v6FPDJwnVe4nuSh5gdPAQQxhPQyNL1uE0PxvvrXDhF8_G7-5wM20e9d0Dsbc9FFPSZ8DdHZ5-jf_PLX_oYjtdjdOAYc9tdJ83GgAz1RJhRrbfmFut9XOpMPPy1HQayMy5VhM0T7YnIlAFguOZgo4g==" rel="nofollow" target="_blank" rel="nofollow">https://www.facebook.com/NasdaqBTCS</a></p> <p><strong>Investor Relations:</strong><br />Charles Allen - CEO<br />X: <a href="https://www.globenewswire.com/Tracker?data=I8f8V8GtXpzPWe33tREGKgxpeXbEXG8jFs_z7dAev_bzIIhGuhXAcrZXlQgc1XI4sK8gxHbYqb7IKALp8P1prig0XgpIB0Vslfwqd0LO33w=" rel="nofollow" target="_blank" rel="nofollow"><em>@Charles_BTCS</em></a><br />Email: <a href="https://www.globenewswire.com/Tracker?data=FYa3LUZbAeMNDwfz8-qqizEG_QOC2Q9SOEfo6bmfNgsB22iLKf2pzMuQxgpXZ_wnWNJEUOOwOsBMoqawK7dduA==" rel="nofollow" target="_blank" rel="nofollow"><em> [email protected] </em></a></p> <p><strong>KCSA Strategic Communications</strong><br />Valter Pinto - Managing Director<br />Email: <a href="https://www.globenewswire.com/Tracker?data=IiawsskJMKu3ku_bwrSmdcjz7H-CxKW4QImKVqP52S479F2vhaO4sFAXEcua5LCNny_B8JstJcV2I6hFK7-cOQ==" rel="nofollow" target="_blank" rel="nofollow"><em> [email protected] </em></a><br />Tel: (212) 896-1254</p> <p><strong>Financials</strong></p> <p>The tables below are derived from the Company's financial statements included in its Form 10-K filed on March 26, 2026, with the Securities and Exchange Commission. Please refer to the Form 10-K for complete financial statements and further information regarding the Company's results of operations and financial condition relating to the fiscal quarter and fiscal year ended December 31, 2025 and 2024. The Company's Form 10-K also includes a discussion of risk factors applicable to the Company and its business.</p> <table style="border-collapse: collapse; width:100%; border-collapse:collapse ;"> <tr> <td colspan="9" style="text-align: center ; vertical-align: middle; vertical-align: bottom ; "><strong>BTCS Inc.<br />Balance Sheets<br /></strong></td> </tr> <tr> <td colspan="9" style="vertical-align: bottom ; "> </td> </tr> <tr> <td style="vertical-align: bottom ; "> </td> <td style="vertical-align: bottom ; "> </td> <td colspan="2" style="text-align: center ; vertical-align: middle; vertical-align: bottom ; "><strong>December 31,</strong></td> <td style="vertical-align: bottom ; "> </td> <td style="vertical-align: bottom ; "> </td> <td colspan="2" style="text-align: center ; vertical-align: middle; vertical-align: bottom ; "><strong>December 31,</strong></td> <td style="vertical-align: bottom ; "> </td> </tr> <tr> <td style="vertical-align: bottom ; "> </td> <td style="vertical-align: bottom ; "> </td> <td colspan="2" style="border-bottom: solid black 1pt ; text-align: center ; vertical-align: middle; vertical-align: bottom ; "><strong>2025</strong></td> <td style="vertical-align: bottom ; "> </td> <td style="vertical-align: bottom ; "> </td> <td colspan="2" style="border-bottom: solid black 1pt ; text-align: center ; vertical-align: middle; vertical-align: bottom ; "><strong>2024</strong></td> <td style="vertical-align: bottom ; "> </td> </tr> <tr> <td style="vertical-align: bottom ; "> </td> <td style="vertical-align: bottom ; "> </td> <td colspan="2" style="vertical-align: bottom ; "> </td> <td style="vertical-align: bottom ; "> </td> <td style="vertical-align: bottom ; "> </td> <td colspan="2" style="text-align: center ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="vertical-align: bottom ; "> </td> </tr> <tr> <td style="max-width:64%; width:64%; min-width:64%;;vertical-align: bottom ; "><strong>Assets:</strong></td> <td style="max-width:1%; width:1%; min-width:1%;;vertical-align: bottom ; "> </td> <td style="max-width:1%; width:1%; min-width:1%;;vertical-align: bottom ; "> </td> <td style="max-width:15%; width:15%; min-width:15%;;text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="max-width:1%; width:1%; min-width:1%;;vertical-align: bottom ; "> </td> <td style="max-width:1%; width:1%; min-width:1%;;vertical-align: bottom ; "> </td> <td style="max-width:1%; width:1%; min-width:1%;;vertical-align: bottom ; "> </td> <td style="max-width:15%; width:15%; min-width:15%;;text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="max-width:1%; width:1%; min-width:1%;;vertical-align: bottom ; "> </td> </tr> <tr> <td style="vertical-align: bottom ; ">Current assets:</td> <td style="vertical-align: bottom ; "> </td> <td style="vertical-align: bottom ; "> </td> <td style="text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="vertical-align: bottom ; "> </td> <td style="vertical-align: bottom ; "> </td> <td style="vertical-align: bottom ; "> </td> <td style="text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="vertical-align: bottom ; "> </td> </tr> <tr> <td style="vertical-align: middle; text-align: left; padding-left: 15.0px; vertical-align: bottom ; ">Cash and cash equivalents</td> <td style="vertical-align: bottom ; "> </td> <td style="vertical-align: bottom ; ">$</td> <td style="text-align: right ; vertical-align: middle; vertical-align: bottom ; ">1,526,395</td> <td style="vertical-align: bottom ; "> </td> <td style="vertical-align: bottom ; "> </td> <td style="vertical-align: bottom ; ">$</td> <td style="text-align: right ; vertical-align: middle; vertical-align: bottom ; ">1,977,778</td> <td style="vertical-align: bottom ; "> </td> </tr> <tr> <td style="vertical-align: middle; text-align: left; padding-left: 15.0px; vertical-align: bottom ; ">Stablecoins</td> <td style="vertical-align: bottom ; "> </td> <td style="vertical-align: bottom ; "> </td> <td style="text-align: right ; vertical-align: middle; vertical-align: bottom ; ">1,539,064</td> <td style="vertical-align: bottom ; "> </td> <td style="vertical-align: bottom ; "> </td> <td style="vertical-align: bottom ; "> </td> <td style="text-align: right ; vertical-align: middle; vertical-align: bottom ; ">39,545</td> <td style="vertical-align: bottom ; "> </td> </tr> <tr> <td style="vertical-align: middle; text-align: left; padding-left: 15.0px; vertical-align: bottom ; ">Digital assets - treasury</td> <td style="vertical-align: bottom ; "> </td> <td style="vertical-align: bottom ; "> </td> <td style="text-align: right ; vertical-align: middle; vertical-align: bottom ; ">2,388,607</td> <td style="vertical-align: bottom ; "> </td> <td style="vertical-align: bottom ; "> </td> <td style="vertical-align: bottom ; "> </td> <td style="text-align: right ; vertical-align: middle; vertical-align: bottom ; ">646,539</td> <td style="vertical-align: bottom ; "> </td> </tr> <tr> <td style="vertical-align: middle; text-align: left; padding-left: 15.0px; vertical-align: bottom ; ">Digital assets - DeFi</td> <td style="vertical-align: bottom ; "> </td> <td style="vertical-align: bottom ; "> </td> <td style="text-align: right ; vertical-align: middle; vertical-align: bottom ; ">177,718,244</td> <td style="vertical-align: bottom ; "> </td> <td style="vertical-align: bottom ; "> </td> <td style="vertical-align: bottom ; "> </td> <td style="text-align: right ; vertical-align: middle; vertical-align: bottom ; ">-</td> <td style="vertical-align: bottom ; "> </td> </tr> <tr> <td style="vertical-align: middle; text-align: left; padding-left: 15.0px; vertical-align: bottom ; ">Digital assets - staked</td> <td style="vertical-align: bottom ; "> </td> <td style="vertical-align: bottom ; "> </td> <td style="text-align: right ; vertical-align: middle; vertical-align: bottom ; ">30,657,401</td> <td style="vertical-align: bottom ; "> </td> <td style="vertical-align: bottom ; "> </td> <td style="vertical-align: bottom ; "> </td> <td style="text-align: right ; vertical-align: middle; vertical-align: bottom ; ">35,410,144</td> <td style="vertical-align: bottom ; "> </td> </tr> <tr> <td style="vertical-align: middle; text-align: left; padding-left: 15.0px; vertical-align: bottom ; ">Non-fungible tokens</td> <td style="vertical-align: bottom ; "> </td> <td style="vertical-align: bottom ; "> </td> <td style="text-align: right ; vertical-align: middle; vertical-align: bottom ; ">41,690</td> <td style="vertical-align: bottom ; "> </td> <td style="vertical-align: bottom ; "> </td> <td style="vertical-align: bottom ; "> </td> <td style="text-align: right ; vertical-align: middle; vertical-align: bottom ; ">-</td> <td style="vertical-align: bottom ; "> </td> </tr> <tr> <td style="vertical-align: middle; text-align: left; padding-left: 15.0px; vertical-align: bottom ; ">Prepaid expenses</td> <td style="vertical-align: bottom ; "> </td> <td style="border-bottom: solid black 1pt ; vertical-align: bottom ; "> </td> <td style="border-bottom: solid black 1pt ; text-align: right ; vertical-align: middle; vertical-align: bottom ; ">146,031</td> <td style="vertical-align: bottom ; "> </td> <td style="vertical-align: bottom ; "> </td> <td style="border-bottom: solid black 1pt ; vertical-align: bottom ; "> </td> <td style="border-bottom: solid black 1pt ; text-align: right ; vertical-align: middle; vertical-align: bottom ; ">63,934</td> <td style="vertical-align: bottom ; "> </td> </tr> <tr> <td style="vertical-align: bottom ; ">Total current assets</td> <td style="vertical-align: bottom ; "> </td> <td style="border-bottom: solid black 1pt ; vertical-align: bottom ; "> </td> <td style="border-bottom: solid black 1pt ; text-align: right ; vertical-align: middle; vertical-align: bottom ; ">214,017,432</td> <td style="vertical-align: bottom ; "> </td> <td style="vertical-align: bottom ; "> </td> <td style="border-bottom: solid black 1pt ; vertical-align: bottom ; "> </td> <td style="border-bottom: solid black 1pt ; text-align: right ; vertical-align: middle; vertical-align: bottom ; ">38,137,940</td> <td style="vertical-align: bottom ; "> </td> </tr> <tr> <td style="vertical-align: bottom ; "> </td> <td style="vertical-align: bottom ; "> </td> <td style="vertical-align: bottom ; "> </td> <td style="text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="vertical-align: bottom ; "> </td> <td style="vertical-align: bottom ; "> </td> <td style="vertical-align: bottom ; "> </td> <td style="text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="vertical-align: bottom ; "> </td> </tr> <tr> <td style="vertical-align: bottom ; ">Other assets:</td> <td style="vertical-align: bottom ; "> </td> <td style="vertical-align: bottom ; "> </td> <td style="text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="vertical-align: bottom ; "> </td> <td style="vertical-align: bottom ; "> </td> <td style="vertical-align: bottom ; "> </td> <td style="text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="vertical-align: bottom ; "> </td> </tr> <tr> <td style="vertical-align: middle; text-align: left; padding-left: 15.0px; vertical-align: bottom ; ">Investments, at value (Cost $600,000)</td> <td style="vertical-align: bottom ; "> </td> <td style="vertical-align: bottom ; "> </td> <td style="text-align: right ; vertical-align: middle; vertical-align: bottom ; ">600,000</td> <td style="vertical-align: bottom ; "> </td> <td style="vertical-align: bottom ; "> </td> <td style="vertical-align: bottom ; "> </td> <td style="text-align: right ; vertical-align: middle; vertical-align: bottom ; ">100,000</td> <td style="vertical-align: bottom ; "> </td> </tr> <tr> <td style="vertical-align: middle; text-align: left; padding-left: 15.0px; vertical-align: bottom ; ">Property and equipment, net</td> <td style="vertical-align: bottom ; "> </td> <td style="border-bottom: solid black 1pt ; vertical-align: bottom ; "> </td> <td style="border-bottom: solid black 1pt ; text-align: right ; vertical-align: middle; vertical-align: bottom ; ">14,390</td> <td style="vertical-align: bottom ; "> </td> <td style="vertical-align: bottom ; "> </td> <td style="border-bottom: solid black 1pt ; vertical-align: bottom ; "> </td> <td style="border-bottom: solid black 1pt ; text-align: right ; vertical-align: middle; vertical-align: bottom ; ">7,449</td> <td style="vertical-align: bottom ; "> </td> </tr> <tr> <td style="vertical-align: bottom ; ">Total other assets</td> <td style="vertical-align: bottom ; "> </td> <td style="border-bottom: solid black 1pt ; vertical-align: bottom ; "> </td> <td style="border-bottom: solid black 1pt ; text-align: right ; vertical-align: middle; vertical-align: bottom ; ">614,390</td> <td style="vertical-align: bottom ; "> </td> <td style="vertical-align: bottom ; "> </td> <td style="border-bottom: solid black 1pt ; vertical-align: bottom ; "> </td> <td style="border-bottom: solid black 1pt ; text-align: right ; vertical-align: middle; vertical-align: bottom ; ">107,449</td> <td style="vertical-align: bottom ; "> </td> </tr> <tr> <td style="vertical-align: bottom ; "> </td> <td style="vertical-align: bottom ; "> </td> <td style="vertical-align: bottom ; "> </td> <td style="text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="vertical-align: bottom ; "> </td> <td style="vertical-align: bottom ; "> </td> <td style="vertical-align: bottom ; "> </td> <td style="text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="vertical-align: bottom ; "> </td> </tr> <tr> <td style="vertical-align: bottom ; ">Total Assets</td> <td style="vertical-align: bottom ; "> </td> <td style="border-bottom: double black 3pt ; vertical-align: bottom ; ">$</td> <td style="border-bottom: double black 3pt ; text-align: right ; vertical-align: middle; vertical-align: bottom ; ">214,631,822</td> <td style="vertical-align: bottom ; "> </td> <td style="vertical-align: bottom ; "> </td> <td style="border-bottom: double black 3pt ; vertical-align: bottom ; ">$</td> <td style="border-bottom: double black 3pt ; text-align: right ; vertical-align: middle; vertical-align: bottom ; ">38,245,389</td> <td style="vertical-align: bottom ; "> </td> </tr> <tr> <td style="vertical-align: bottom ; "> </td> <td style="vertical-align: bottom ; "> </td> <td style="vertical-align: bottom ; "> </td> <td style="text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="vertical-align: bottom ; "> </td> <td style="vertical-align: bottom ; "> </td> <td style="vertical-align: bottom ; "> </td> <td style="text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="vertical-align: bottom ; "> </td> </tr> <tr> <td style="vertical-align: bottom ; "><strong>Liabilities and Stockholders' Equity:</strong></td> <td style="vertical-align: bottom ; "> </td> <td style="vertical-align: bottom ; "> </td> <td style="text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="vertical-align: bottom ; "> </td> <td style="vertical-align: bottom ; "> </td> <td style="vertical-align: bottom ; "> </td> <td style="text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="vertical-align: bottom ; "> </td> </tr> <tr> <td style="vertical-align: bottom ; ">Current liabilities:</td> <td style="vertical-align: bottom ; "> </td> <td style="vertical-align: bottom ; "> </td> <td style="text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="vertical-align: bottom ; "> </td> <td style="vertical-align: bottom ; "> </td> <td style="vertical-align: bottom ; "> </td> <td style="text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="vertical-align: bottom ; "> </td> </tr> <tr> <td style="vertical-align: middle; text-align: left; padding-left: 15.0px; vertical-align: bottom ; ">Accounts payable and accrued expenses</td> <td style="vertical-align: bottom ; "> </td> <td style="vertical-align: bottom ; ">$</td> <td style="text-align: right ; vertical-align: middle; vertical-align: bottom ; ">38,525</td> <td style="vertical-align: bottom ; "> </td> <td style="vertical-align: bottom ; "> </td> <td style="vertical-align: bottom ; ">$</td> <td style="text-align: right ; vertical-align: middle; vertical-align: bottom ; ">70,444</td> <td style="vertical-align: bottom ; "> </td> </tr> <tr> <td style="vertical-align: middle; text-align: left; padding-left: 15.0px; vertical-align: bottom ; ">Accrued compensation</td> <td style="vertical-align: bottom ; "> </td> <td style="vertical-align: bottom ; "> </td> <td style="text-align: right ; vertical-align: middle; vertical-align: bottom ; ">1,609,208</td> <td style="vertical-align: bottom ; "> </td> <td style="vertical-align: bottom ; "> </td> <td style="vertical-align: bottom ; "> </td> <td style="text-align: right ; vertical-align: middle; vertical-align: bottom ; ">3,907,091</td> <td style="vertical-align: bottom ; "> </td> </tr> <tr> <td style="vertical-align: middle; text-align: left; padding-left: 15.0px; vertical-align: bottom ; ">Accrued interest</td> <td style="vertical-align: bottom ; "> </td> <td style="vertical-align: bottom ; "> </td> <td style="text-align: right ; vertical-align: middle; vertical-align: bottom ; ">225,115</td> <td style="vertical-align: bottom ; "> </td> <td style="vertical-align: bottom ; "> </td> <td style="vertical-align: bottom ; "> </td> <td style="text-align: right ; vertical-align: middle; vertical-align: bottom ; ">-</td> <td style="vertical-align: bottom ; "> </td> </tr> <tr> <td style="vertical-align: middle; text-align: left; padding-left: 15.0px; vertical-align: bottom ; ">Loans payable - DeFi protocol</td> <td style="vertical-align: bottom ; "> </td> <td style="vertical-align: bottom ; "> </td> <td style="text-align: right ; vertical-align: middle; vertical-align: bottom ; ">61,500,000</td> <td style="vertical-align: bottom ; "> </td> <td style="vertical-align: bottom ; "> </td> <td style="vertical-align: bottom ; "> </td> <td style="text-align: right ; vertical-align: middle; vertical-align: bottom ; ">-</td> <td style="vertical-align: bottom ; "> </td> </tr> <tr> <td style="vertical-align: middle; text-align: left; padding-left: 15.0px; vertical-align: bottom ; ">Warrant liabilities</td> <td style="vertical-align: bottom ; "> </td> <td style="vertical-align: bottom ; "> </td> <td style="text-align: right ; vertical-align: middle; vertical-align: bottom ; ">-</td> <td style="vertical-align: bottom ; "> </td> <td style="vertical-align: bottom ; "> </td> <td style="vertical-align: bottom ; "> </td> <td style="text-align: right ; vertical-align: middle; vertical-align: bottom ; ">267,900</td> <td style="vertical-align: bottom ; "> </td> </tr> <tr> <td style="vertical-align: bottom ; ">Total current liabilities</td> <td style="vertical-align: bottom ; "> </td> <td style="border-bottom: solid black 1pt ; vertical-align: bottom ; "> </td> <td style="border-bottom: solid black 1pt ; text-align: right ; vertical-align: middle; vertical-align: bottom ; ">63,372,848</td> <td style="vertical-align: bottom ; "> </td> <td style="vertical-align: bottom ; "> </td> <td style="border-bottom: solid black 1pt ; vertical-align: bottom ; "> </td> <td style="border-bottom: solid black 1pt ; text-align: right ; vertical-align: middle; vertical-align: bottom ; ">4,245,435</td> <td style="vertical-align: bottom ; "> </td> </tr> <tr> <td style="vertical-align: bottom ; "> </td> <td style="vertical-align: bottom ; "> </td> <td style="vertical-align: bottom ; "> </td> <td style="text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="vertical-align: bottom ; "> </td> <td style="vertical-align: bottom ; "> </td> <td style="vertical-align: bottom ; "> </td> <td style="text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="vertical-align: bottom ; "> </td> </tr> <tr> <td style="vertical-align: bottom ; ">Non-current liabilities:</td> <td style="vertical-align: bottom ; "> </td> <td style="vertical-align: bottom ; "> </td> <td style="text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="vertical-align: bottom ; "> </td> <td style="vertical-align: bottom ; "> </td> <td style="vertical-align: bottom ; "> </td> <td style="text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="vertical-align: bottom ; "> </td> </tr> <tr> <td style="vertical-align: bottom ; ">Convertible notes payable, net</td> <td style="vertical-align: bottom ; "> </td> <td style="border-bottom: solid black 1pt ; vertical-align: bottom ; ">$</td> <td style="border-bottom: solid black 1pt ; text-align: right ; vertical-align: middle; ...</tr></table><p><a href=https://www.benzinga.com/pressreleases/26/03/g51504506/btcs-reports-305-year-over-year-revenue-growth-to-record-16-5-million-for-full-year-2025?utm_source=benzinga_taxonomy&utm_medium=rss_feed_free&utm_content=taxonomy_rss&utm_campaign=channel alt=BTCS Reports 305% Year-Over-Year Revenue Growth to Record $16.5 Million for Full Year 2025>Full story available on Benzinga.com</a></p>

#STOCKS

herefordtimeshace 8d

Mercado de Talgarth: precios récord en medio de la escasez de existencias

El mercado ganadero de Talgarth alcanza precios récord para los cerdos y las ovejas de desecho en medio de una grave escasez de existencias en el Reino Unido, con picos de venta de cerdos a £242 y ovejas de Texel a £235.

#STOCKS

globenewswire_frhace 8d

Senti Bio informa los resultados financieros del cuarto trimestre y del año completo 2025 y proporciona una actualización corporativa

SOUTH SAN FRANCISCO, California, 27 de marzo de 2026 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), una empresa de biotecnología en etapa clínica que desarrolla terapias celulares y genéticas de próxima generación utilizando su plataforma patentada Gene Circuit, informó hoy los resultados financieros para el cuarto trimestre de 2025 y el año completo 2025 y proporcionó un resumen de los aspectos más destacados corporativos y en desarrollo recientes.

#STOCKS

invezzhace 8d

SoftBank obtiene un préstamo de 40.000 millones de dólares para profundizar la asociación con OpenAI

SoftBank ha obtenido un préstamo puente de 40.000 millones de dólares a medida que agudiza su enfoque en la inteligencia artificial y amplía su relación con OpenAI, la empresa detrás de ChatGPT. La medida señala un renovado impulso por parte del gigante inversor japonés para posicionarse en el centro del mercado de IA generativa de rápido crecimiento. Dirigido por Masayoshi Son, SoftBank está redoblando su apuesta por la IA después de un período marcado por la volatilidad en su cartera Vision Fund. Se espera que la financiación respalde tanto su estrategia de inversión OpenAI como necesidades corporativas más amplias. Estructura de préstamo y socios bancarios El préstamo puente no está garantizado y vencerá en marzo de 2027, lo que le dará a SoftBank flexibilidad a medida que despliega capital en sus ambiciones de IA. La financiación se concertó con un grupo de...

#STOCKS